A strategic region for global clinical trials.
📊 30–50% lower costs compared to North America and Europe
👥 660+ million people, with high availability of naïve patients (never participated in trials)
⚡ Faster recruitment: fewer sites needed to meet patient targets, reducing costs and increasing data quality
🧬 High ethnic diversity – including European, Japanese, African, and Indigenous populations
🏥 Robust infrastructure with centralized healthcare, efficient patient tracking, and regional distribution
📋 Regulatory alignment: Brazil is an ICH member since 2016 – allowing data to be used for FDA, EMA, and others
💉 Rare disease potential: Easier access to underrepresented populations, especially in hard-to-recruit indications
LATAM’s Leading CRO Partner with Global Reach
🏆 #1 LATAM-based CRO, with 26+ years of experience
🌐 6 countries of operation across Latin America
📈 550+ clinical studies conducted
🤝 90% of sponsors are international (US, EMEA, JAPAC)
🧠 Multidisciplinary, senior team with strong global experience in all phases (I–IV) and therapeutic areas
🔬 End-to-end services: From regulatory strategy to biostatistics, logistics, QA, and more
🧭 Flexible delivery model tailored to each sponsor’s needs
⚙️ International quality standards in every study
🔄 Agility & responsiveness thanks to our boutique CRO model
🛡️ Proactive risk management to ensure operational and design success
LATAM: Brazil, Argentina, Mexico, Chile, Colombia, Peru
Sponsors from: USA, UK, Germany, Switzerland, Japan, China, South Korea, and more
🔹 Biotech (US): Patient enrollment in LATAM countries doubled the total from 21 other countries – at a lower cost per patient
🔹 Biotech (Japan): Rare disease study expanded across LATAM with Intrials – resulting in successful outcomes and new regional investments
🔹 Biotech (Switzerland): Intrials led a gene therapy trial with FDA-level data quality using LATAM patient base
Ready to explore LATAM with a trusted CRO partner?
Visit intrials.com.br or contact us to start planning your study with confidence.